| CYP17 gene polymorphism and its association with high-risk north Indian breast cancer patients. | |
| | |
MedLine Citation:
|
PMID: 17235448 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
A single T > C change at the 5' promoter region of the CYP17 gene is reported to be associated with increased risk of breast cancer. This study evaluates the influence of genetic polymorphism of CYP17 on breast cancer susceptibility. Two hundred and forty-two patients with histopathologically confirmed breast cancer and 212 age-matched controls were included in the present study. Information relating to age at onset of the disease, family history and estrogen receptor status was elicited. Investigation for CYP17 polymorphism was carried out in 106 early onset, 80 late onset and 56 familial cases. The frequencies of two CYP17 alleles were also analyzed in 116 (47.9%) cases with known estrogen receptor (ER) status confirmed immunohistochemically. A polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method was used to detect the polymorphism, and the genotypes identified were assigned as homozygous wild type (A1A1), heterozygous variant (A1A2), and homozygous variant (A2A2). Associations between the various genotypes in patients and controls were investigated with Fisher's exact test. All the tests were two tailed. The results showed that the frequency of heterozygous and homozygous CYP17 genotype was higher in early onset breast cancer patients (94.3%) than in controls (80.3%), and the difference was significant (P = 0.001). A highly statistically significant increased risk in carriers of homozygous A2 allele was found in young patients (P < or = 0.001) in comparison with patients having late onset condition (P = 0.260). However, no significant association between the genotype and breast cancer risk was observed among women with strong family history. Further, data had showed that patients (80.6%) with at least one A2 allele tended to exhibit ER-independent cell proliferation, although statistical significance could not be established (P = 0.160). The present findings suggest that CYP17 A2 allele gene polymorphism might play a significant role in breast cancer development in young Indian women. |
| | |
Authors:
|
Anurupa Chakraborty; N S Murthy; Chintamani Chintamani; D Bhatnagar; R S Mohil; P C Sharma; Sunita Saxena |
Related Documents
:
|
7697828 - Cytochrome p4501a1 gene polymorphism and homozygous deletion of the glutathione s-trans... 18571008 - Genetic susceptibility of epidermal growth factor +61a>g and transforming growth factor... 15577288 - Associations between bmi, energy intake, energy expenditure, vdr genotype and colon and... 20406958 - Refining the prostate cancer genetic association within the jazf1 gene on chromosome 7p... 14689068 - Serum thrombopoietin levels in patients with reactive thrombocytosis due to lung cancer... 21401248 - Perceived susceptibility to breast cancer moderates the effect of gain- and loss-framed... |
Publication Detail:
|
Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't Date: 2007-01-18 |
Journal Detail:
|
Title: Journal of human genetics Volume: 52 ISSN: 1434-5161 ISO Abbreviation: J. Hum. Genet. Publication Date: 2007 |
Date Detail:
|
Created Date: 2007-01-30 Completed Date: 2007-03-13 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9808008 Medline TA: J Hum Genet Country: Japan |
Other Details:
|
Languages: eng Pagination: 159-65 Citation Subset: IM |
Affiliation:
|
Institute of Pathology, Safdarjang Hospital Campus, New Delhi, India. sunita_saxena@yahoo.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Aged Aged, 80 and over Breast Neoplasms / epidemiology, genetics* Case-Control Studies Female Genetic Predisposition to Disease Genotype Humans India / epidemiology Middle Aged Polymerase Chain Reaction Polymorphism, Genetic / genetics* Polymorphism, Restriction Fragment Length Risk Factors Steroid 17-alpha-Hydroxylase / genetics* |
| Chemical | |
Reg. No./Substance:
|
EC 1.14.99.9/Steroid 17-alpha-Hydroxylase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: 'Postconditioning' the human heart: multiple balloon inflations during primary angioplasty may confe...
Next Document: Frequency of the LRRK2 G2019S mutation in Italian patients affected by Parkinson's disease.